Edit
Recro Pharma
http://www.recropharma.com/Last activity: 21.03.2022
Active - Reference to Recro®
Recro Pharma (NASDAQ:REPH) is a specialty biopharmaceutical company developing differentiated, high value, prescription drugs for analgesia, anesthesia, sedation and other specialty markets. Recro is currently focusing on proprietary drug solutions for chronic pain, breakthrough pain, and acute post-operative pain.
Location: United States, Pennsylvania, Malvern
Employees: 201-500
Founded date: 2007
Investors 1
| Date | Name | Website |
| - | SCP Vitali... | scpvitalif... |
Mentions in press and media 5
| Date | Title | Description |
| 21.03.2022 | After acquisitions and new deals, Recro rebrands to Societal CDMO | The team at Recro, a CDMO based out of Pennsylvania, has made a flurry of moves in the past year, expanding its operations to the West Coast with the acquisition of Irisys, and expanding its dosage forms in the process. Next up: a rebrand. ... |
| 10.11.2021 | Recro Reports Third Quarter 2021 Financial Results | Acquisition of IriSys, Inc. Significantly Expands Customer Pipeline, Facilities and Capabilities Annual Revenue Guidance Increased to between $74 and $76 million Recorded Q3 2021 Revenues of $18.2 Million and Signed Multiple New Business Ag... |
| 10.11.2021 | Recro Reports Third Quarter 2021 Financial Results - Form 8-K | Recro Reports Third Quarter 2021 Financial Results Acquisition of IriSys, Inc. Significantly Expands Customer Pipeline, Facilities and Capabilities Annual Revenue Guidance Increased to between $74 and $76 million Recorded Q3 2021 Revenues o... |
| 09.08.2021 | Recro Pharma : Reports Second Quarter 2021 Financial Results | Q2 2021 Highlighted by Revenues of $18.0 Million, an Increase of 16% Compared to Q2 2020 Revenue Multiple New Business Agreements Continue to Expand and Diversify Customer Base and Pipeline Company Closes Public Financing Raising Net Procee... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |